EuroBiotech: More Articles of Note


> Genfit offloaded the Chinese rights to NASH prospect elafibranor to Terns Pharmaceuticals for $35 million (€31 million) upfront. The deal is worth up to $193 million more in milestones. Statement 

> Boehringer Ingelheim made a milestone payment to Oxford BioTherapeutics after it advanced an oncology drug candidate. Release 

> Vesalius Biocapital closed its third life sciences fund at €120 million. The VC shop had aimed to raise $150 million and close the fund last year. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> C4X Discovery teamed up with PhoreMost to access technology to support its Parkinson’s disease drug discovery activities. Release 

> Poxel and Sumitomo Dainippon posted top-line data from a phase 3 trial of imeglimin in Type 2 diabetes. The trial met its primary endpoint. Statement 

> Allergy Therapeutics secured a $7.6 million settlement through litigation against Inflamax Research. The case centered on whether a phase 2 allergy trial was performed properly. Release 

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.